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African trypanosomes are strictly extracellular protozoan parasites that cause diseases 
in humans and livestock and significantly affect the economic development of sub- 
Saharan Africa. Due to an elaborate and efficient (vector)–parasite–host interplay, 
required to complete their life cycle/transmission, trypanosomes have evolved efficient 
immune escape mechanisms that manipulate the entire host immune response. So far, 
not a single field applicable vaccine exists, and chemotherapy is the only strategy avail-
able to treat the disease. Current therapies, however, exhibit high drug toxicity and an 
increased drug resistance is being reported. In addition, diagnosis is often hampered 
due to the inadequacy of current diagnostic procedures. In the context of tackling 
the shortcomings of current treatment and diagnostic approaches, nanobodies (Nbs, 
derived from the heavy chain-only antibodies of camels and llamas) might represent 
unmet advantages compared to conventional tools. Indeed, the combination of their 
small size, high stability, high affinity, and specificity for their target and tailorability rep-
resents a unique advantage, which is reflected by their broad use in basic and clinical 
research to date. In this article, we will review and discuss (i) diagnostic and therapeutic 
applications of Nbs that are being evaluated in the context of African trypanosomiasis, 
(ii) summarize new strategies that are being developed to optimize their potency for 
advancing their use, and (iii) document on unexpected properties of Nbs, such as 
inherent trypanolytic activities, that besides opening new therapeutic avenues, might 
offer new insight in hidden biological activities of conventional antibodies.
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iNTRODUCTiON
African trypanosomiasis (AT), caused by strictly extracellular unicellular flagellated protozoan 
parasites belonging to the genus Trypanosoma, is a “neglected” disease of medical and veterinary 
importance that significantly affects the socioeconomic development of sub-Saharan Africa (1–5). 
Hereby, AT affects mainly remote rural areas with minimal health infrastructure and its distribution 
coincides mostly with the habitat of the hematophagous insect vector, i.e., the tsetse fly (Glossina sp.) 
(6). In humans, the disease is known as human African trypanosomiasis (HAT) or sleeping sickness, 
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and is caused by (i) Trypanosoma brucei gambiense (Western and 
central Africa) which is an anthroponotic disease with a minor 
role for animal reservoirs accounting for 98% of the reported 
HAT cases, and causing a chronic, gradually progressing disease 
with limited symptoms, whereby the late meningoencephalitic 
stage is reached after months/years of infection (7–9), and 
(ii) Trypanosoma brucei rhodesiense (Eastern/southern Africa) 
which is a zoonotic disease affecting mainly animals (livestock 
and wildlife), with humans being only occasionally infected, and 
representing 2% of the reported HAT cases, whereby the infec-
tions are more acute and virulent/lethal with a rapid progression 
(within weeks) to the late meningoencephalitic stage (3, 9–12). 
Hence, the zoonotic nature of T. b. rhodesiense infections makes 
them more difficult to control compared to T. b. gambiense 
infections (8, 13, 14). Animal African trypanosomiasis (AAT) 
or Nagana is the second form of AT affecting sub-Saharan 
Africa, which is mainly caused by Trypanosoma congolense, 
Trypanosoma vivax, and to a lesser extent Trypanosoma brucei 
brucei, whereas Surra and Dourine are also forms of AAT 
caused by Trypanosoma evansi and Trypanosoma equiperdum, 
respectively (15–17). Overall, T. congolense is a major constraint 
for livestock production in sub-Saharan Africa, whereby cattle 
succumb to infection primarily due to parasite-induced anemia 
or complications resulting from secondary, opportunistic infec-
tions (18). In addition, the estimated annual losses associated 
with AAT are about US$5 billion (1, 19–21), which is mainly due 
to a combined result of political, sociocultural, environmental, 
entomological, and livestock management factors (22–24). So 
far, chemotherapy is the only strategy available to treat the dis-
ease, whereby unique organelles of trypanosomes (glycosomes or 
kinetoplast) that are absent in the mammalian host or trypano-
some metabolic pathways that differ from their host counterparts 
(carbohydrate metabolism, protein and lipid modifications, 
and programmed cell death) are targeted (25–27). Given that 
chemotherapy is associated with high drug toxicity, there is 
an urgent need to optimize trypanocide usage and delivery in 
order to decrease the risk of toxicity and/or resistance develop-
ment (28–30). Control of AT is also hampered due to inefficient 
diagnosis of the infection especially for AAT and T. b. rhodesiense 
HAT where microscopical parasite detection (cheap but with 
low sensitivity), detection of the parasite’s DNA (expensive but 
with high sensitivity), or anti-parasite antibodies remain the 
only available tools for diagnosis. Yet, these techniques require 
specialized equipment and personnel and hence are not suitable 
for direct use in the field. Only for T. b. gambiense, monitoring 
tools are available for both detection and staging of the disease 
(4, 31–33). Existing field applicable antibody-based diagnostic 
tests still suffer from a lack of positive predictive value and cannot 
differentiate between active or cured infections (32, 34, 35). Direct 
diagnosis aimed at parasite antigen detection is often hampered 
by sequestration of parasite antigens by the host’s antibodies 
or by concealing of epitopes from the diagnostic monoclonal 
antibodies (mAbs) (36). Although immunodiagnostics based 
on antigen detection would be preferable, they are currently not 
available for trypanosomiasis in the field (32).
In contrast to conventional antibodies, nanobodies [Nbs or 
VHHs, i.e., camelid-derived single-domain antibody fragments 
(~15 kDa) that are selected through phage display technology 
and panning methodologies] (37, 38) could be used to overcome 
certain challenges faced by mAb-based tests (see above). Hereby, 
Nbs exhibit characteristic features such as (i) a nanomolar affinity 
for their target (39), (ii) a unique epitope recognition spectrum 
different from conventional antibodies, thereby allowing detec-
tion of both free antigens and those bound by host antibodies 
(40), (iii) high solubility (40), (iv) easy tailorability (multimeriza-
tion or tagging) for molecular imaging and drug-delivery appli-
cations (41–44), and (v) small size that circumvents problems 
of tissue or blood–brain barrier (BBB) penetrability (44, 45). 
Due to these unique biochemical and biophysical properties, 
they are considered as promising next-generation therapeutics 
with great potential in pharmaceutical and industrial applica-
tions (46, 47). Indeed, Nbs are increasingly exploited in protein 
structure/function studies and in the development of alternative 
or new medical diagnostic and therapeutic applications (48, 49). 
Nbs also possess a relatively high thermostability (50, 51) and 
are consequently attractive for the development of immunodi-
agnostic tests that could be applicable in hot climatic conditions 
(i.e., sub-Saharan Africa).
In the next sections, we will give an overview of how the Nb 
technology can be implemented in the fight against AT both at the 
level of diagnosis and treatment and finally how acquired knowl-
edge on Nbs in AT might lead to new insights in the function of 
conventional antibodies in the immune system.
LiFe CYCLe OF AFRiCAN 
TRYPANOSOMeS
In order to point out at which stages Nbs might be applicable 
to fight AT, it is appropriate to overview briefly their life cycle. 
African trypanosomes exhibit a digenetic life cycle, alternating 
between the blood/tissues of the mammalian host and alimen-
tary tract of the tsetse fly vector, whereby they exist as procyclic 
or trypomastigote forms (52), respectively (see Figure  1). The 
lifecycle within the mammalian host is initiated upon the bite 
of a trypanosome-infected tsetse fly when taking a blood meal 
(see Figure 1). Hereby, metacyclic parasites are inoculated in the 
host dermis in concert with tsetse saliva components that play 
a key role in the modulation of the host early immune response 
and in sculpturing an immune privileged microenvironment 
for infection initiation (53–55). From the dermal infection site, 
parasites reach the blood circulation through the lymphatics 
(55). Subsequently, these metacyclic parasites expressing a het-
erogeneous metacyclic variable surface glycoprotein (VSG) coat 
will differentiate into dividing long slender (LS) bloodstream 
dividing forms (BF), which express a unique VSG coat and are 
adapted to survive in the glucose-rich and highly oxygenated 
blood of the mammalian host. Next, these BFs rapidly multiply, 
giving rise to a first parasitemia peak. At the peak of parasitemia, 
most likely via a quorum sensing mechanism (56, 57), the LS 
parasites differentiate into non-dividing short stumpy (SS) 
forms pre-adapted for survival in the tsetse fly vector. Within 
the tsetse fly vector, these SS forms differentiate within the 
midgut into procyclic forms (PF) that express a procyclin coat, 
FigURe 1 | Life cycle of African trypanosomes. (1) Upon the bite of a trypanosome-infected tsetse fly, metacyclic parasites (trypomastigotes) and saliva 
components (such as Tsal) are inoculated into the mammalian host. (2) The metacyclic parasites [expressing a heterogeneous metacyclic variable surface 
glycoprotein (VSG)] differentiate into long slender (LS) trypomastigotes (i.e., LS, dividing/proliferating forms, expressing a unique bloodstream form VSG) giving rise 
to a first peak of parasitemia. (3) At the peak of parasitemia, these LS forms differentiate into non-dividing short stumpy (SS) forms that are pre-adapted to be taken 
up by the vector. (4) Upon taking a blood meal, these SS forms are ingested and in the midgut these parasites differentiate into procyclic forms (PF), whereby the 
coat is switched toward procyclin. (5) The PF differentiate into epimastigote forms when migrating to the proventriculus (expressing a bloodstream alanine rich 
protein coat). (6) Upon migration to the salivary glands, the parasites differentiate into metacyclic forms that are ready to complete their life cycle.
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which are adapted to survive in the proline-rich (carbon source) 
and low-oxygenated environment. Within the tsetse fly, these 
parasites undergo several differentiation stages in the different 
parts of the alimentary tract, mouthparts, and salivary glands 
(58, 59). In order to adapt to the growth conditions imposed by 
the different environments of their hosts, trypanosomes undergo 
essential morphological and metabolic changes (52), consisting 
of fine-tuning their energy metabolism, a dedicated iron and 
nutrient uptake, organelle reorganization, and biochemical and 
ultrastructural remodeling (60–65). Hence, tools to interfere with 
the various stages in the parasite life cycle might be an attractive 
strategy to combat AT.
Nbs AS veRSATiLe TOOLS FOR AT
The control over AT would benefit from more efficient diag-
nosis and treatment intervention strategies. Hereby, since their 
serendipitous discovery 30  years ago, Nbs attracted a progres-
sively growing interest from fundamental research on antibody 
structure and ontogeny to diagnostical and therapeutical 
applications (66–68). With respect to fundamental research, the 
Nb technology was found to provide a novel tool in structural 
biology, whereby they can be used as crystallization-aid, or as a 
tool to design novel drugs based on co-crystallization of Nbs with 
their cognate antigen (69, 70). Although such applications in the 
field of AT are not yet documented, this will most likely become 
an emerging field of study in the near future. Moreover, given 
the tremendous efforts to identify novel targets for AT through 
proteomic approaches (71), the merging of the Nb technology 
with the current technologies might pave the way to develop 
additional tools/targets to fight AT. In this section, we will give 
an overview of the applications of the Nb technology in the field 
of AT.
Nbs As Tools for Diagnosis
To date, several obstacles hamper an efficient and reliable diag-
nosis of AT, whereby (i) inefficient antibody-based detection 
due to interferences caused by the host’s antibody response (i.e., 
antibodies remaining in circulation for long periods of time) 
impairs discrimination between active and cured infections and 
(ii) antigen-based trypanosome detection methods that might 
allow circumventing the problems encountered in the antibody-
based detection system are not yet available. In this context, Nbs 
are emerging as promising tools to overcome the limitations of 
TAbLe 1 | Overview of the different targets against which nanobodies (Nbs) have been generated.
Target vector PF bF Specificity Diagnosis Treatment Reference
Tsal + − − Saliva + − (72)
Procyclin − + − Tb ? ? –
Aldolase − − + Tc + ? (78)
Paraflagellar rod protein − + + Te, Tb, Tc, Tv + ? (77)
Conserved variable surface glycoprotein (VSG) epitope − − + Tb, (Tc?) + + (81)
Variable VSG epitope − − + Tb, (Tc?) + + (98)
Transferrin receptor − ? + Tb, Tc, Te, Tv ? ? –
In addition, the Nb specificity and applicability (diagnosis/treatment) is mentioned.
PF, procyclic forms; BP, bloodstream form; Tb, Trypanosoma brucei; Tc, Trypanosoma congolense; Te, Trypanosoma evansi; Tv, Trypanosoma vivax.
Trypanosome species in bold refers to the species against which the target was originally generated.
“?” stands for not tested or unknown.
FigURe 2 | Overview of strategies used to generate nanobodies (Nbs) and their applications. Nbs can be obtained from llama’s that are either immunized with 
factors derived from (i) tsetse flies (i.e., sialome or procyclin coat isolated form procyclic forms) or (ii) purified blood stream parasites originally grown in the 
mammalian host [i.e., secretome, soluble lysate, or variable surface glycoprotein (VSG)] or (iii) from infected (naturally or experimentally) with trypanosomes. After 
immunization, lymphocytes are isolated from the blood and via the PCR, phage display, and different selection procedures, individual Nbs can be obtained and 
purified. These Nbs can find application in diagnosis, therapy, or be used for fundamental research aiming at developing novel strategies to fight African 
trypanosomiasis.
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antibody-based diagnosis and to improve antigen-based detec-
tion of African trypanosomes (see Figure 2 and Table 1). For 
instance, though the binding interference caused by the host’s 
antibody response upon infection might hamper  sensitive 
detection, this response might also be exploited using the Nb 
technology. Indeed, Caljon et  al. (72) showed that following 
immunization of an alpaca with the sialome of the savannah 
tsetse fly vector (Glossina morsitans morsitans), Nbs could be 
generated against an abundant highly immunogenic tsetse sali-
vary gland (Tsal) endonuclease protein and could subsequently 
be used to monitor tsetse fly bite exposure (73). Monitoring this 
bite exposure level in a target host population is important as 
the probability of a trypanosome transmission event to a new 
host is directly linked to the exposure level of the host to tsetse 
bites in that area (=risk factor). Indeed, only a very limited 
number of flies in a natural tsetse population carries the final 
infective parasite stage, so the more frequent a host is bitten 
by tsetse the higher the risk is that it will trap a trypanosome 
infection through the bite of a rarely occurring infected fly in 
that area. The assay principle relies on the detection of specific 
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anti-Tsal1 antibodies in an assay that measures the competi-
tive binding onto the immunogenic Tsal1protein of diagnostic 
Nbs (Tsal1Nb-5 and -11) and host antibodies that are typically 
induced by bite exposure. This Nb-based competition assay 
allows specific detection of exposure to a range of important 
tsetse fly species in the context of sero-epidemiological surveys 
based on salivary proteins. This could not only allow monitoring/ 
estimating the intensity of the host exposure to tsetse fly bites 
but also reveal the efficacy of applied and/or ongoing tsetse fly 
control activities. This approach might be further extended by 
generating anti-proteome and/or anti-infectome Nb libraries 
in order to identify diagnostic Nbs (74–76). Indeed, the work 
by Obishakin et  al. (77) showed that upon immunization of a 
llama with T. evansi lysate, Nbs against the paraflagellar rod 
(PFR) protein of trypanosomes could be generated and used in 
a solid phase antigen-ELISA to detect this protein in different 
T. evansi strains. Although the assay was not sensitive enough 
to detect T. congolense and T. vivax lysates in ELISA, one of the 
anti-PFR Nbs (Nb392) was found to cross-react with multiple 
parasite species such as T. brucei, T. congolense, and T. vivax as 
well as PF. Detection was achieved using fixed and permeabi-
lized parasites and via flow cytometry and immunofluorescence 
microscopy, inferring that this Nb could be used to develop a 
broad spectrum diagnostic reagent. Moreover, this Nb could 
also be exploited as a PFR marker and/or as a useful research 
tool to isolate PFR proteins. More recently, Odongo et al. (78) 
identified following immunization of a llama with the soluble 
proteome of bloodstream form (BF) T. congolense a Nb (Nb474) 
recognizing glycosomal aldolase (TcoALD) that could be used 
in a Nb-based sandwich ELISA to specifically detect active 
T. congolense infections in experimentally and naturally infected 
cattle. In experimental T. congolense infection models, parasitemia 
and detected antigenemia followed the same trend and the assay 
was suggested to be suitable as a test of cure. Although no formal 
detection limit was determined, the Nb474-based test was able 
to detect T. congolense infections in two field collected cattle 
blood samples that underwent the traditional parasitological 
diagnosis using the buffy coat technique followed by 18S-PCR-
RFLP-based parasite species identification. Furthermore, it was 
suggested that the robustness of this Nb474-ELISA to specifically 
monitor T. congolense infections in the field might be improved 
once the structural and biophysical determinants of the specific 
Nb474–TcoALD interaction can be determined. Of note, also in 
other parasitic diseases such as malaria, aldolase was reported 
as a proficient biomarker for the detection of Plasmodium vivax 
(79). In addition, in regions of sub-Saharan Africa where animals 
are infected with human and animal infective trypanosomes, 
this selective test for T. congolense using aldolase as a biomarker 
would allow discriminating between the two parasite groups, 
hence enabling assessment of the potential risk for human 
infection (80).
Besides recognizing low abundant proteins, Nbs have also 
been generated against the highly abundant VSG coat of the 
T. congolense parasite, yet due to the system of antigenic varia-
tion their diagnostic value is rather limited (unpublished data). 
However, the work by Stijlemans et al. (81), using the T. brucei 
model parasites, showed that the reduced size of a Nb allows to 
target conserved, less-immunogenic, cryptic VSG epitopes, that 
are inaccessible to conventional antibodies. Hereby, the fluores-
cently labeled anti-VSG Nb-33 was found to be very proficient to 
detect different isoforms of the T. brucei family and to specifically 
stain trypanosomes in infected blood. This suggests that even Nbs 
directed against specific conserved regions of the VSG molecule 
can be used as diagnostic tools.
Collectively, these data suggest that a Nb-based strategy could 
be a unique approach for diagnosis development and might 
bring us a step closer toward obtaining an antigen-detection test 
that can be used for rapid and reliable detection of vector expo-
sure as well as the presence of pathogen infections in reservoir 
hosts (see Figure  2 and Table  1). In addition, Nbs could also 
be used for target discovery given that following immunizations 
with complex protein mixtures and via different purification 
techniques, their cognate antigens with diagnostic potential can 
be identified.
Nbs As Therapeutic Devices
Nbs As Tools for Drug/Toxin Delivery
Although the currently used chemotherapeutics are proficient 
in killing trypanosomes, their in vivo application suffers from 
systemic drug toxicity and occurrence of drug resistance (82). 
Therefore, delivering the chemotherapeutic (or toxin) directly 
to the parasite could be a more efficient way for treating AT. 
The possibility of using Nbs as targeting entity was investigated 
using the Nb-33 as model Nb (Figure 2; Table 1). With respect 
to using Nb-33 as a toxin-delivery system to African trypano-
somes, apolipoprotein L-1 (ApoL-1) was selected as a trypano-
lytic component. ApoL-1 is a component of normal human 
serum (NHS) that exerts a direct trypanolytic effect on all AAT 
species, except resistant forms such as T. brucei rhodesiense  
(83). Indeed, T. b. rhodesiense expresses the apoL-I-neutralizing 
serum resistance-associated (SRA) protein, endowing this para-
site with the ability to infect humans and cause HAT (83, 84). 
Hence, Nb-33, recognizing a conserved/cryptic region within 
the VSG coat, was coupled to a truncated form of Apo-L1 (i.e., 
Tr-apoL-1), which is engineered by deleting the SRA-interacting 
domain. This engineered immunotoxin was shown to function 
curatively and to alleviate effects on acute and chronic infections 
in mice infected with both NHS-resistant and sensitive parasites 
(85, 86). The Nb-33 was also used as a delivery system for thera-
peutics using T. b. gambiense parasites as a model. Hereby, nano-
particles loaded with pentamidine [i.e., drug used for treating 
the early disease stage, before central nervous system involve-
ment (87), as the second-line option to suramin] were coupled 
to Nb-33. This targeted drug-bullet allowed decreasing the half-
inhibitory concentration (IC50) 7-fold compared to free drug 
in vitro and cured all mice at a 10-fold lower dose than the mini-
mal full curative dose of free pentamidine (88–90). Moreover, 
recently an improved version of this nanocarrier allowed reduc-
ing the curative dose 100-fold and circumvented drug resistance 
that is due to mutations in aquaglyceroporin 2 (i.e., the surface 
channel protein that mediates pentamidine uptake in T. brucei) 
(29, 91, 92). Overall, targeting the trypanosome surface using 
Nb-coated drug-loaded nanoparticles can be an elegant way to 
deliver drugs via endocytosis and bypass the usual drug delivery 
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route altogether. Recently, using the Nb-33, it was shown that 
Nbs are able to pass the BBB during the late stage of T. brucei 
infection using murine and rat models, which suggests they 
might be valuable tools to target toxins even at the levels of 
the BBB. Yet, they were incapable of accumulating in the brain 
at therapeutically relevant concentrations (93), which is most 
likely due to the systemic pharmacokinetics of monovalent Nbs 
(42, 94). Hence, efforts should be undertaken to tailor these 
Nbs via for instance CDR grafting to yield improved brain 
penetrating properties without losing their beneficial size 
(95, 96). In addition, to quantitatively study the penetration of 
Nbs into the CNS in vivo, intracerebral microdialysis represents 
a powerful and sensitive technique. Given that much effort is put 
into developing new drugs against African trypanosomes, the 
Nb-based drug/toxin-delivery approach might allow increas-
ing their efficacy, even against drug resistant parasites, and be 
applicable for many other diseases (97).
Nbs As Direct Trypanolytic Entities by Blocking 
Endocytosis
By serendipity, besides a drug-targeting potential, Nbs were 
found to exert direct trypanolytic activities. Indeed, it was 
shown that some Nbs specific for the variable part of VSG of 
T. b. brucei parasites were able to induce parasite lysis in vitro. 
The lytic process consists of a rapid immobilization of the para-
sites, followed by massive enlargement of the flagellar pocket and 
a major blockage of endocytosis (98). Given that endocytosis is 
essential for trypanosome survival, playing a key role in nutrient 
uptake and in regulating intracellular ATP-levels as well as in 
maintaining the mitochondrial membrane potential, it is a prime 
candidate target for therapeutic interventions (99). Moreover, 
the endocytosis is confined to the flagellar pocket, which can 
be considered as the gateway to and from the cell surface that 
regulates the host–parasite interface as well as significantly 
contributes toward interactions with therapeutics. Hence, this 
might be the trypanosomal Achilles’ heel and offer perspec-
tives for directed drug delivery focusing on proteins essential 
in endocytosis (100). Also, targeting specific receptors essential 
for nutrient uptake could be considered as therapeutic targets. 
For instance, given that iron is essential for the survival of 
both the trypanosome and the mammalian host and that their 
receptor for iron/transferrin uptake differs (i.e., a heterodimer 
and homodimer, respectively) (101), specific targeting of the 
parasite transferrin receptor using Nbs might be an opportunity 
to selectively deprive trypanosomes from this essential nutrient 
or alternatively be used as drug delivery or diagnostic tool. Also, 
the fact that low-molecular weight VSG-specific trypanolytic 
Nbs can impede endocytosis suggests that Nbs can be used as 
tools to further unravel the fascinating endocytosis mechanism 
used by trypanosomes. This in turn may offer new opportunities 
for developing novel trypanosomiasis therapeutics aimed at 
affecting endocytosis.
One aspect that could compromise the therapeutic appli-
cations of Nbs, in for instance HAT patients, is the potential 
immunogenicity of Nbs, especially in treatments that require 
repeated injections. Currently, the immunogenicity of Nb-based 
therapeutic applications is controversial. For instance, a 
clinical trial study conducted by GSK revealed the occurrence 
of anti-TNFR1 Nb autoantibodies and in another study with a 
tetravalent anti-DR5 receptor Nb hepatotoxicity in patients with 
such pre-existing antibodies has been described (102, 103). By 
contrast, no anti-HER2 Nb autoantibodies could not be detected 
in patients who received a non-humanized Nb (104), nor in 
patients receiving a Nb against von Willebrand factor (105). 
Also in the murine model, so far, multiple injections of Nbs in 
different disease settings did not result in immunogenicity, nei-
ther at the level of specific antibodies against Nbs nor at the level 
of cell proliferation and cytokine levels (68, 106–108). Hence, it 
seems that the occurrence of immunogenicity might depend on 
the target and disease situation (46). Yet, to reduce/minimize the 
risk of an immune response within the mammalian host, there 
are strategies currently implemented, such as humanization of 
the Nbs, whereby the camelid-specific amino acid sequences are 
mutated to their human heavy chain variable domain equiva-
lent. In this context, a universal humanized Nb scaffold has 
been generated that allows grafting the antigen-binding loops 
from other Nbs, thereby transferring the antigen specificity and 
affinity (109).
Paratransgenesis As Tool to Deliver Nbs  
within the Tsetse Fly Vector
The applications of Nbs against AT may be not restricted to the 
BF of the parasites within the mammalian host, but could be 
applied/extrapolated to the vector. In this context, the possibility 
to exploit the tsetse fly bacterial symbiont Sodalis glossinidius 
as a paratransgenic platform organism for the expression and 
delivery of trypanosome-interfering proteins (i.e., Nbs) within 
the tsetse fly vector was evaluated. To this end, both the non-lytic 
Nb-33 and the trypanolytic Nbs were shown to be successfully 
expressed without affecting S. glossinidius fitness/viability (110). 
Moreover, using the trypanolytic Nb as proof of concept, recom-
binant S. glossinidius could settle in different tsetse fly tissues 
at high densities. Furthermore, significant levels of functional 
anti-trypanosome Nbs were released in several tissues including 
the midgut where important developmental stages of the parasite 
reside (111). Here, the level of Nb expression was estimated to 
be in the low nanogram (<10  ng), which was calculated to be 
sufficient to lyse the expected low number of transforming blood 
stream trypanosomes (around 103 parasites) in the tsetse midgut 
during the early developmental period after ingestion by the fly 
(111). Accordingly, this paratransgenic approach using Sodalis to 
deliver Nbs that target the parasite or the trypanosome–tsetse 
fly cross talk could open new avenues to unravel the molecular 
determinants of this specific parasite–vector interplay and to 
ultimately render tsetse flies trypanosome resistant [reviewed by 
Caljon et al. (112)]. Given that the trypanosome is not exposed 
to an adaptive immune system in the tsetse vector, this parasite 
stage is not undergoing antigenic variation with the major surface 
antigen being encoded by a limited set of procyclin genes. In this 
context, the potential of Nbs delivered using the Sodalis endo-
symbiont targeting the major developmental stages in the tsetse 
fly, such as the procyclic trypanosomes that need to overcome 
the midgut barrier in order to achieve colonization of the tsetse 
fly vector, is currently being investigated. Stable integration of 
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Nb expression cassettes in the Sodalis genome (e.g., by using 
recently established procedures) and efficient vertical transfer 
of the transgenic Sodalis have been achieved (113). Important 
issues, such as the identification of highly potent infection-
blocking Nbs and the increased proteolytic stability, are still to 
be addressed (114). The latter feature will be highly beneficial to 
maintain potent effector levels in the strong proteolytic diges-
tive environment of the insect midgut. Yet, such strategies could 
potentially culminate in a drug-targeting strategy to eliminate 
trypanosomes within the tsetse fly vector. An important achieve-
ment in the context of the Sodalis-based paratransgenesis is the 
efficient transfer of genetically modified Sodalis from the mother 
tsetse fly to its offspring through intrauterine nourishment (113). 
This implies that a large-scale tsetse fly colony can be established 
of flies harboring a Nb-expressing Sodalis. The paratransgenic 
trypanosome-resistant male flies from these colonies can then 
be released (after sterilization through irradiation) at a mas-
sive scale in the context of the Sterile Insect Technique (SIT). 
SIT was already successfully used to eradicate the tsetse fly in 
Zanzibar and is currently an important pillar in the tsetse fly 
control campaigns in Ethiopia and Senegal (http://www.fao.
org/in-action/senegal-celebrates-first-victory-against-tsetse-fly- 
eradication/en/).
LYTiC Nbs: ReLevANCe IN VIVO?
The observation that the antigen-binding domain (i.e., Nb) 
on itself, in the absence of the Fc part can exert a significant 
Fc-independent killing of African trypanosomes in  vitro and 
in vivo is remarkable (98). Moreover, it was found that both the 
size and affinity were of crucial importance for this trypanolytic 
activity (98, 115). Indeed, whereas polyclonal antibodies (includ-
ing heavy-chain antibodies) specific for the VSG of African 
trypanosomes are completely harmless to trypanosomes in the 
absence of complement or any other bystander effector (116, 117), 
polyclonal Fabs or Nbs derived from the serum antibody pools 
and monoclonal/polyclonal Fabs or Nbs that are deprived of all 
effector functions (i.e., Fc) could exhibit an intrinsic trypano-
lytic activity in  vitro (98). It is surprising that removal of the 
Fc part from antibodies unveils a novel but deadly situation, 
because trypanosomes and other extracellular pathogens mostly 
coped during evolution with intact immunoglobulins and thus 
developed multiple ways to avoid the destructive action of such 
large molecules (118, 119). In case of African trypanosomes 
such escape mechanisms include (i) antigenic variation of the 
VSGs, (ii) dense packing of VSG molecules on the parasite’s coat 
prohibiting the recognition of conserved and/or physiologically 
important epitopes by intact antibodies, (iii) clearing of VSG-
bound antibodies by endocytosis of the VSG–antibody complex 
[reviewed in Ref. (120–123)]. In contrast to intact Abs, the 
small-sized Fabs or Nbs may penetrate the dense VSG coat and 
trigger new processes or avoid removal of VSG–antibody com-
plexes, which is dictated by the bivalency of Abs (possibly due to 
cross-linking of the VSGs) and/or antibody size, e.g., whereby 
the presence of the Fc part leads to steric occlusion (123, 124).
The concept that the Fc part within an antibody is masking the 
intrinsic destructive capacity of the antigen-binding fragment 
is intriguing. Consequently, other polyclonal or mAbs may 
share similar features and harbor hidden activities that remain 
occluded within intact Abs and might manifest themselves upon 
generation of monovalent Fabs or Nbs (see Figure 3). Evidence 
for a possible intrinsic anti-pathogen activity of in vivo generated 
Fabs or Nbs within the bona fide antibody independent of the 
Fc part is difficult to provide as there is so far no simple assay 
to demonstrate such an event. Nevertheless, such mechanisms 
might exist as Nbs with competitive enzyme-inhibiting activ-
ity or Fabs with catalytic activity (termed Abzymes) have been 
identified (117–120). Under certain conditions, antibodies were 
documented to exert bactericidal activities in the absence of com-
plement or phagocytes (125). For instance, antibodies catalyze the 
generation of hydrogen peroxide (H2O2) from singlet molecular 
oxygen and water, thereby producing an additional molecular 
species with a chemical signature similar to that of ozone (126). 
Interestingly, this singlet molecular oxygen is only present when 
the host is under assault, thereby making it an “event-triggered” 
substrate and consequently suggests that the additional function 
of an antibody might only be apparent under “inflammatory” 
conditions (127). In addition, it was shown that high H2O2 in 
concert with transition metal ions (FeCl2) (i.e., factors that are 
typically produced/released via apoptotic neutrophils during 
inflammation) can generate hydroxyl radicals (via a Fenton-like 
reaction) that induce hinge fragmentation of IgG1 mAb [(128) 
consisting of (i) a Fab domain and the upper hinge of one of 
the Fc domains and (ii) another Fab domain linked to the Fc 
domain (see proposed model in Figure 3)]. This indicates that 
under certain in vivo inflammatory conditions hidden biological 
activities could become unmasked from bona fide antibodies. 
To the best of our knowledge, the observation that an antibody-
derived fragment on itself can exert a biological function is a new 
conceptual insight which might broaden the potentiality of Ab 
applications in different fields.
CONCLUSiON AND FUTURe 
PeRSPeCTiveS
Over the years, Nbs have been found to be valuable tools in 
the field of AT both at the level of diagnosis and treatment. 
They were shown to have potential to circumvent problems 
encountered with antibody-based detection systems and in 
addition allow the development of antigen-based approaches 
that were so far lacking (32). With the era of proteomics (71), 
allowing additional biomarkers to be discovered, the applica-
tion of a Nb-based immunoproteomic approach might allow 
developing more efficient tools to improve trypanosomiasis 
control (diagnosis/treatment) in the near future. With respect 
to treatment against AT, it seems that Nbs are a very proficient 
tool to deliver drugs/toxins to parasites, thereby reducing the 
side effects due to drug toxicity and possibly the probability to 
develop drug resistance. Their small size, low immunogenicity, 
and tailorability furthermore favor their application in AT with 
respect to BBB drug delivery, routine/systemic administration, 
and generation of half-life extended formats. Also for research 
purposes, their advantages are increasingly appreciated and 
FigURe 3 | Proposed model of “hidden” functions of antibodies during inflammation. (Left panel) Through genetic engineering, camelid-derived heavy-chain 
antibodies (HCAbs) can be fragmented to the size of a nanobody that might exert a direct effect on pathogens (i.e., trypanosomes). (Right panel) (1) During infection 
(i.e., trypanosome infection), parasite-derived factors in concert with host-derived factors trigger macrophage (Mϕ) activation. (2) Hereby, elicited antibodies 
opsonize parasites and in concert with complement trigger parasite destruction, further leading to release of macrophage activating components and inflammatory 
responses. (3) The local inflammation may lead to recruitment, activation, and apoptosis of neutrophils. (4) Release of H2O2 as well as transitional metal ions and 
proteases by neutrophils/activated macrophages can fragment intact IgG (1). (5) Next, this will induce hinge fragmentation of IgG1 giving rise to a fragmented 
antibody into moieties including the Fab domain. (6) This Fab domain might exert a direct lytic effect on trypanosomes.
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they will most likely become a useful tool with respect to crys-
tallization and imaging. Finally, the concept that a Nb or a Fab 
fragment derived from an intact IgG might exert a biological 
function by itself in the absence of the Fc-bystander warrants 
further investigation. Moreover, this suggests that intact anti-
bodies harbor hidden functions that only become apparent 
upon fragmentation into a Fab, a process that might occur 
under certain conditions, and this might have a broad range of 
implications and applications in other diseases.
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